DNA

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). • Tenaya Therapeutics shares are powering higher. What’s behind TNYA gains? The collaboration...

Microsoft Corporation co-founder Bill Gates has spoken about the fake polio vaccination campaign orchestrated by former U.S. President Barack Obama’s administration to locate Osama bin Laden in Pakistan. What Happened: In an interview with The Times U.K. which was published on Friday,...

Genome sequencing company Illumina Inc (NASDAQ: ILMN) has transformed its business over the years with a handful of acquisitions and new product launches. An acquisition in 2006 was one of the most important in company history and also rewarded investors along the way. What Happened: Illumina...

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets....

A SPAC deal announced Thursday will see a company working on a new protein sequencing on a chip go public.  The SPAC Deal: Semiconductor company Quantum-Si is going public in a SPAC merger with HighCape Capital Acquisition Corp (NASDAQ: CAPA). The deal values Quantum-Si at $925 million. An...

Some of the best performing ETFs in 2020 have been the Ark Funds, actively managed ETFs led by Cathie Wood. A long-time Tesla Inc (NASDAQ: TSLA) and technology stock bull, Wood is now betting heavily on genomic stocks. Wood On Genomics: Genomic stocks are expected to drive strong returns for the...

DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ: ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.  The Analyst Derik de Bruin downgraded Illumina from...

The bearish case for Illumina, Inc. (NASDAQ: ILMN) has come to an end for four key reasons, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded Illumina from Underweight to Equal-weight with a price target lifted from $210 to $320. The Thesis Illumina stands to benefit from...

In a story first reported by Nikkei and updated recently by Le Monde, Sony Corp. (NYSE: SNE) and U.S. genome sequencing equipment maker Illumina Inc. (NASDAQ: ILMN) plan to launch a human genome analysis project in October. The project will involve the study and analysis of genetic material...